Antiphospholipid antibodies are not elevated in patients with severe COVID-19 pneumonia and venous thromboembolism

Galeano Valle, FranciscoOblitas, Christian-MarioFerreiro Mazón, M.M.Alonso Muñoz, L.Toro Cervera, Jorge delDemelo Rodríguez, Pablo2025-12-192025-12-192020Galeano-Valle F, Oblitas CM, Ferreiro-Mazón MM, Alonso-Muñoz J, del-Toro-Cervera J, Demelo-Rodríguez P. Antiphospholipid antibodies are not elevated in patients with severe COVID-19 pneumonia and venous thromboembolism. Thromb Res. 2020;192:113-115. doi: 10.1016/j.thromres.2020.05.017. Epub 2020 May 15.0049-384810.1016/j.thromres.2020.05.017https://hdl.handle.net/20.500.14352/129428COVID-19 pneumonia could be associated with an increased risk of venous thrombosis. Antiphospholipid antibodies might be involved in thrombosis in COVID-19 patients. Prevalence of antiphospholipid antibodies in COVID-19 and venous thrombosis was low.engAntiphospholipid antibodies are not elevated in patients with severe COVID-19 pneumonia and venous thromboembolismjournal article1879-2472https://doi.org/10.1016/j.thromres.2020.05.017http://sciencedirect.com/science/article/pii/S0049384820301894?via%3Dihubhttps://pubmed.ncbi.nlm.nih.gov/32425261/restricted accessCiencias Biomédicas32 Ciencias Médicas